Niko

# Niko ## Overview - **Classification**: Novel Macrolide Antibiotic - **Mechanism**: Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Primarily bacteriostatic, can be bactericidal at higher concentrations. ## Primary Indications 1. **Community-Acquired Pneumonia (CAP)** - Treatment of mild-to-moderate CAP. 2. **Skin and Soft Tissue Infections (SSTIs)** - Uncomplicated SSTIs caused by susceptible organisms. 3. **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - For exacerbations caused by susceptible bacteria. ## Adult Dosing ### Standard Dosing **Community-Acquired Pneumonia (CAP)** - **Dose**: **500 mg** - **Frequency**: **Once daily (QD)** - **Route**: Oral (PO) - **Duration**: **7-10 days** **Skin and Soft Tissue Infections (SSTIs)** - **Dose**: **250 mg** - **Frequency**: **Twice daily (BID)** - **Route**: Oral (PO) - **Duration**: **5-7 days** **Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB)** - **Dose**: **500 mg** - **Frequency**: **Once daily (QD)** - **Route**: Oral (PO) - **Duration**: **5 days** ### Dose Adjustments - **Renal Impairment**: No adjustment for CrCl >30 mL/min. For CrCl **<30 mL/min**, reduce dose by **50%**. - **Hepatic Impairment**: Use with caution in severe impairment; monitor LFTs closely. Dose reduction may be necessary based on clinical response and tolerability. - **Elderly Patients**: No specific dose adjustment solely based on age. Consider underlying renal function. ## Pediatric Dosing ### Neonates (0-28 days) - **Dose**: **10 mg/kg** - **Frequency**: **Every 24 hours (q24h)** - **Maximum**: **10 mg/kg/dose** - **Special Notes**: Avoid in term neonates <7 days due to risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). Oral suspension or IV formulation only. ### Infants (1-12 months) - **Dose**: **10-15 mg/kg** - **Frequency**: **Every 12-24 hours (q12-24h)** - **Maximum**: **500 mg/day** - **Special Notes**: Use oral suspension; ensure accurate dosing with calibrated device. ### Children (1-12 years) - **Dose**: **10-15 mg/kg** - **Frequency**: **Every 12-24 hours (q12-24h)** - **Maximum**: **500 mg/day** - **Special Notes**: Consider chewable tablets or oral suspension for younger children. ### Adolescents (13-18 years) - **Dose**: Generally follow **adult dosing** recommendations. - **Maximum**: **500 mg/day** ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to Niko or other macrolide antibiotics. - **Absolute**: History of cholestatic jaundice/hepatic dysfunction associated with prior macrolide use. - **Absolute**: Concomitant use with drugs known to prolong the QT interval (e.g., cisapride, pimozide). ### Common Adverse Effects - **Very Common (>10%)**: Nausea, Diarrhea, Abdominal pain, Vomiting. - **Common (1-10%)**: Headache, Dizziness, Rash, Taste disturbance. - **Serious but Rare**: QT prolongation, Torsades de Pointes, Hepatotoxicity, Clostridioides difficile-associated diarrhea (CDAD), Infantile Hypertrophic Pyloric Stenosis (IHPS) in neonates. ### Key Drug Interactions - **QT-prolonging drugs (e.g., antiarrhythmics, antipsychotics)**: Increased risk of Torsades de Pointes. **Avoid concomitant use.** - **Warfarin**: Enhanced anticoagulant effect due to CYP inhibition. **Monitor INR closely.** - **Statins (e.g., simvastatin, atorvastatin)**: Increased risk of myopathy/rhabdomyolysis. **Consider dose reduction or alternative statin.** - **Digoxin**: May increase digoxin serum concentrations. **Monitor digoxin levels.** ## Monitoring & Follow-up - **Before Treatment**: Baseline Liver Function Tests (LFTs) in patients with pre-existing hepatic impairment. - **During Treatment**: Monitor for signs of hepatotoxicity (e.g., jaundice, dark urine), cardiac arrhythmias (palpitations, syncope). - **Clinical Signs**: Resolution of infection symptoms (e.g., fever, cough, wound healing). Watch for persistent or severe diarrhea (CDAD). ## Clinical Pearls - 💡 **Tip 1**: Administer Niko with food to minimize gastrointestinal upset, although this may slightly reduce absorption. - 💡 **Tip 2**: Counsel patients to complete the entire prescribed course of treatment, even if symptoms improve earlier. - 💡 **Tip 3**: Advise patients to immediately report any signs of liver problems (e.g., dark urine, yellowing of skin/eyes, unusual fatigue). > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.